Increased Use of Immunohistochemistry in Medicare Patients with Melanoma Diagnoses Raises Concerns about Appropriate Utilization
The use of immunohistochemistry (IHC) claims associated with Medicare melanoma diagnoses has increased significantly from 11% in 2000 to 51% in 2017, with substantial geographic variation in practice patterns, suggesting the need for research to optimize IHC use in melanoma diagnosis.